{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:12:15Z","timestamp":1792789935085,"version":"4.5.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-023-08963-3","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T07:03:03Z","timestamp":1687244583000},"page":"86-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity"],"prefix":"10.1007","volume":"65","author":[{"given":"Rithika","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Timilsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"8963_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","volume":"348","author":"JJ Lipsky","year":"1996","unstructured":"Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357\u20131359","journal-title":"Lancet"},{"key":"8963_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0065-2164(01)48005-1","volume":"48","author":"R Bentley","year":"2001","unstructured":"Bentley R (2001) Bartolomeo Gosio, 1863\u20131944: an appreciation. Adv Appl Microbiol 48:229\u2013250","journal-title":"Adv Appl Microbiol"},{"key":"8963_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/1523-1747.ep12610346","volume":"65","author":"EL Jones","year":"1975","unstructured":"Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P (1975) Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65:537\u2013542","journal-title":"J Invest Dermatol"},{"key":"8963_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0190-9622(79)80097-3","volume":"1","author":"EC Gomez","year":"1979","unstructured":"Gomez EC, Menendez L, Frost P (1979) Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1:531\u2013537","journal-title":"J Am Acad Dermatol"},{"key":"8963_CR5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/j.1875-9114.1997.tb03082.x","volume":"17","author":"TM Sievers","year":"1997","unstructured":"Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD (1997) Mycophenolate mofetil. Pharmacotherapy 17:1178\u20131197","journal-title":"Pharmacotherapy"},{"key":"8963_CR6","doi-asserted-by":"crossref","unstructured":"(1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345:1321\u20131325","DOI":"10.1016\/S0140-6736(95)92534-1"},{"key":"8963_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"HW Sollinger","year":"1995","unstructured":"Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225\u2013232","journal-title":"Transplantation"},{"key":"8963_CR8","doi-asserted-by":"crossref","unstructured":"(1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 61:1029\u20131037","DOI":"10.1097\/00007890-199604150-00008"},{"key":"8963_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00007890-199101000-00003","volume":"51","author":"KP Platz","year":"1991","unstructured":"Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC (1991) RS-61443\u2013a new, potent immunosuppressive agent. Transplantation 51:27\u201331","journal-title":"Transplantation"},{"key":"8963_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/j.1552-4604.1996.tb04207.x","volume":"36","author":"R Bullingham","year":"1996","unstructured":"Bullingham R, Monroe S, Nicholls A, Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315\u2013324","journal-title":"J Clin Pharmacol"},{"key":"8963_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429\u2013455","journal-title":"Clin Pharmacokinet"},{"key":"8963_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/FTD.0000000000000031","volume":"36","author":"S Alexander","year":"2014","unstructured":"Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, Jacob CK, John GT (2014) Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit 36:423\u2013432","journal-title":"Ther Drug Monit"},{"key":"8963_CR13","first-page":"466","volume":"16","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Lu Y, Song G, Wang Y, Chen J, Xiao C, Zhong L, Sun X, Peng Z, Wang X (2018) In vitro study on influences of UGT1A8 gene polymorphisms on mycophenolate mofetil metabolism. Exp Clin Transplant 16:466\u2013472","journal-title":"Exp Clin Transplant"},{"key":"8963_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00391-021-01907-6","volume":"55","author":"I Coskun Benlidayi","year":"2022","unstructured":"Coskun Benlidayi I, Gokce Kutsal Y (2022) Antirheumatic drugs in older adults and polypharmacy issues. Z Gerontol Geriatr 55:507\u2013512","journal-title":"Z Gerontol Geriatr"},{"key":"8963_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1023\/A:1011909827909","volume":"23","author":"KK Viktil","year":"2001","unstructured":"Viktil KK, Enstad M, Kutschera J, Smedstad LM, Schj\u00f8tt J (2001) Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharm World Sci 23:153\u2013158","journal-title":"Pharm World Sci"},{"key":"8963_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1177\/0091270011412968","volume":"52","author":"MG Kees","year":"2012","unstructured":"Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, Bucher M, Faerber L (2012) Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 52:1265\u20131272","journal-title":"J Clin Pharmacol"},{"key":"8963_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1067\/mcp.2000.111480","volume":"68","author":"M Morii","year":"2000","unstructured":"Morii M, Ueno K, Ogawa A et al (2000) Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 68:613\u2013616","journal-title":"Clin Pharmacol Ther"},{"key":"8963_CR18","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.2165\/0003495-200868170-00007","volume":"68","author":"M Sanford","year":"2008","unstructured":"Sanford M, Keating GM (2008) Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs 68:2505\u20132533","journal-title":"Drugs"},{"key":"8963_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/BOR.0000000000000799","volume":"33","author":"K Chakrabarti","year":"2021","unstructured":"Chakrabarti K, Frame D, Al Abbas M, McCune WJ (2021) The use of mycophenolate mofetil area under the curve. Curr Opin Rheumatol 33:221\u2013232","journal-title":"Curr Opin Rheumatol"},{"key":"8963_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10067-014-2786-9","volume":"34","author":"A Zabotti","year":"2015","unstructured":"Zabotti A, Baraldo M, Quartuccio L, Sacco S, De Marchi G, De Vita S (2015) Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol 34:171\u2013174","journal-title":"Clin Rheumatol"},{"key":"8963_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10409238.2020.1832438","volume":"56","author":"V Pareek","year":"2021","unstructured":"Pareek V, Pedley AM, Benkovic SJ (2021) Human de novo purine biosynthesis. Crit Rev Biochem Mol Biol 56:1\u201316","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"8963_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85\u2013118","journal-title":"Immunopharmacology"},{"key":"8963_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IJNRD.S335371","volume":"14","author":"ME Alamilla-Sanchez","year":"2021","unstructured":"Alamilla-Sanchez ME, Alcala-Salgado MA, Alonso-Bello CD, Fonseca-Gonzalez GT (2021) Mechanism of action and efficacy of immunosupressors in lupus nephritis. Int J Nephrol Renovasc Dis 14:441\u2013458","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"8963_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(75)92661-6","volume":"2","author":"AC Allison","year":"1975","unstructured":"Allison AC, Hovi T, Watts RW, Webster AD (1975) Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2:1179\u20131183","journal-title":"Lancet"},{"key":"8963_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/vaccines10050801","volume":"10","author":"M De Santis","year":"2022","unstructured":"De Santis M, Motta F, Isailovic N et al (2022) Dose-dependent impairment of the immune response to the moderna-1273 mRNA vaccine by mycophenolate mofetil in patients with rheumatic and autoimmune liver diseases. Vaccines (Basel) 10:801","journal-title":"Vaccines (Basel)"},{"key":"8963_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O\u2019Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971\u2013980","journal-title":"N Engl J Med"},{"key":"8963_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1191\/0961203305LU2109OA","volume":"14","author":"A Allison","year":"2005","unstructured":"Allison A (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14:2\u20138","journal-title":"Lupus"},{"key":"8963_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/TP.0b013e3181b0e608","volume":"88","author":"VR Cicinnati","year":"2009","unstructured":"Cicinnati VR, Hou J, Lindemann M, Horn PA, Sotiropoulos GC, Paul A, Gerken G, Beckebaum S (2009) Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation 88:504\u2013513","journal-title":"Transplantation"},{"key":"8963_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-2249.2003.02269.x","volume":"134","author":"M Colic","year":"2003","unstructured":"Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I (2003) Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 134:63\u201369","journal-title":"Clin Exp Immunol"},{"key":"8963_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107025","volume":"91","author":"P Fontova","year":"2021","unstructured":"Fontova P, Rama I, Llaud\u00f3 I et al (2021) Mycophenolic acid interferes the transcriptional regulation and protein trafficking of maturation surface markers in dendritic cells. Int Immunopharmacol 91:107025","journal-title":"Int Immunopharmacol"},{"key":"8963_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13075-020-02356-z","volume":"22","author":"M Shigesaka","year":"2020","unstructured":"Shigesaka M, Ito T, Inaba M et al (2020) Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. Arthritis Res Ther 22:264","journal-title":"Arthritis Res Ther"},{"key":"8963_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937667","volume":"13","author":"A Tonutti","year":"2022","unstructured":"Tonutti A, Motta F, Ceribelli A, Isailovic N, Selmi C, De Santis M (2022) Anti-MDA5 antibody linking COVID-19, type i interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 13:937667","journal-title":"Front Immunol"},{"key":"8963_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clim.2015.03.005","volume":"158","author":"Y Yang","year":"2015","unstructured":"Yang Y, Tang Q, Zhao M et al (2015) The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. Clin Immunol 158:67\u201376","journal-title":"Clin Immunol"},{"key":"8963_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1567-5769(02)00210-2","volume":"3","author":"CA Jonsson","year":"2003","unstructured":"Jonsson CA, Carlsten H (2003) Mycophenolic acid inhibits inosine 5\u2019-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 3:31\u201337","journal-title":"Int Immunopharmacol"},{"key":"8963_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235743","volume":"15","author":"A von Borstel","year":"2020","unstructured":"von Borstel A, Abdulahad WH, Dekkema G, Rutgers A, Stegeman CA, Veldman J, Heeringa P, Sanders JS (2020) Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS ONE 15:e0235743","journal-title":"PLoS ONE"},{"key":"8963_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109130","volume":"111","author":"M Aliyu","year":"2022","unstructured":"Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, Azizi G (2022) Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol 111:109130","journal-title":"Int Immunopharmacol"},{"key":"8963_CR37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1681\/ASN.V1071542","volume":"10","author":"G Remuzzi","year":"1999","unstructured":"Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A (1999) Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542\u20131549","journal-title":"J Am Soc Nephrol"},{"key":"8963_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5414\/CPP41465","volume":"41","author":"C Morath","year":"2003","unstructured":"Morath C, Zeier M (2003) Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 41:465\u2013469","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 17","key":"8963_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","volume":"20","author":"C Morath","year":"2006","unstructured":"Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W (2006) Antifibrotic actions of mycophenolic acid. Clin Transplant 20(Suppl 17):25\u201329","journal-title":"Clin Transplant"},{"key":"8963_CR40","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/j.1600-6143.2008.02322.x","volume":"8","author":"C Morath","year":"2008","unstructured":"Morath C, Reuter H, Simon V et al (2008) Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo. Am J Transplant 8:1786\u20131797","journal-title":"Am J Transplant"},{"key":"8963_CR41","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1111\/jcmm.16434","volume":"25","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhang L, Zhu H et al (2021) Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 25:3511\u20133523","journal-title":"J Cell Mol Med"},{"key":"8963_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2230.2011.04201.x","volume":"37","author":"M Ozgen","year":"2012","unstructured":"Ozgen M, Koca SS, Dagli AF, Gundogdu B, Ustundag B, Isik A (2012) Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol 37:48\u201354","journal-title":"Clin Exp Dermatol"},{"key":"8963_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","volume":"58","author":"C Badid","year":"2000","unstructured":"Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M (2000) Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51\u201361","journal-title":"Kidney Int"},{"key":"8963_CR44","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/08916934.2015.1054027","volume":"48","author":"S Yung","year":"2015","unstructured":"Yung S, Zhang Q, Chau MKM, Chan TM (2015) Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1\/J mice. Autoimmunity 48:471\u2013487","journal-title":"Autoimmunity"},{"key":"8963_CR45","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/art.24573","volume":"60","author":"S Yung","year":"2009","unstructured":"Yung S, Zhang Q, Zhang CZ, Chan KW, Lui SL, Chan TM (2009) Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum 60:2071\u20132082","journal-title":"Arthritis Rheum"},{"issue":"Suppl 131","key":"8963_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.55563\/clinexprheumatol\/g5mej7","volume":"39","author":"L Wollin","year":"2021","unstructured":"Wollin L, Trinh-Minh T, Zhang Y, Distler JHW (2021) The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol 39(Suppl 131):134\u2013141","journal-title":"Clin Exp Rheumatol"},{"key":"8963_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1067\/mjd.2000.104890","volume":"42","author":"M Grundmann-Kollmann","year":"2000","unstructured":"Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU (2000) Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42:835\u2013837","journal-title":"J Am Acad Dermatol"},{"key":"8963_CR48","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","volume":"30","author":"M Schiff","year":"2010","unstructured":"Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613\u2013624","journal-title":"Clin Drug Investig"},{"key":"8963_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/annrheumdis-2021-222021","volume":"81","author":"T N\u00e9meth","year":"2022","unstructured":"N\u00e9meth T, Nagy G, Pap T (2022) Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go? Ann Rheum Dis 81:1055\u20131064","journal-title":"Ann Rheum Dis"},{"key":"8963_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964274","volume":"13","author":"A Grivas","year":"2022","unstructured":"Grivas A, Grigoriou M, Malissovas N, Sentis G, Filia A, Flouda S, Katsimpri P, Verginis P, Boumpas DT (2022) Combined \u2013 whole blood and skin fibroblasts- transcriptomic analysis in Psoriatic Arthritis reveals molecular signatures of activity, resistance and early response to treatment. Front Immunol 13:964274","journal-title":"Front Immunol"},{"key":"8963_CR51","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","volume":"78","author":"E Valenzi","year":"2019","unstructured":"Valenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Trejo Bittar H, Rojas M, Lafyatis R (2019) Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 78:1379\u20131387","journal-title":"Ann Rheum Dis"},{"key":"8963_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/keac234","volume":"62","author":"N Shen","year":"2022","unstructured":"Shen N, Zhou X, Jin X et al (2022) MDA5 expression is associated with TGF-\u03b2-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis. Rheumatology (Oxford) 62:373\u2013383","journal-title":"Rheumatology (Oxford)"},{"key":"8963_CR53","doi-asserted-by":"crossref","unstructured":"Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81\u2013ITC96","DOI":"10.7326\/AITC202006020"},{"key":"8963_CR54","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745","journal-title":"Ann Rheum Dis"},{"key":"8963_CR55","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713\u2013723","journal-title":"Ann Rheum Dis"},{"key":"8963_CR56","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156\u20131162","journal-title":"N Engl J Med"},{"key":"8963_CR57","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","volume":"10","author":"LM Ong","year":"2005","unstructured":"Ong LM, Hooi LS, Lim TO et al (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 10:504\u2013510","journal-title":"Nephrology"},{"key":"8963_CR58","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"8963_CR59","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1681\/ASN.2004080686","volume":"16","author":"Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K, Hong Kong Nephrology Study Group","year":"2005","unstructured":"Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K, Hong Kong Nephrology Study Group (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076\u20131084","journal-title":"J Am Soc Nephrol"},{"key":"8963_CR60","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219\u20132228","journal-title":"N Engl J Med"},{"key":"8963_CR61","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","volume":"61","author":"M Walsh","year":"2013","unstructured":"Walsh M, Solomons N, Lisk L, Jayne DRW (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 61:710\u2013715","journal-title":"Am J Kidney Dis"},{"key":"8963_CR62","first-page":"705","volume":"115","author":"W Hu","year":"2002","unstructured":"Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L (2002) Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 115:705\u2013709","journal-title":"Chin Med J (Engl)"},{"key":"8963_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0961203307081340","volume":"16","author":"J Wang","year":"2007","unstructured":"Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L (2007) Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 16:707\u2013712","journal-title":"Lupus"},{"issue":"Suppl 1","key":"8963_CR64","doi-asserted-by":"publisher","first-page":"s33","DOI":"10.1177\/096120330501400107","volume":"14","author":"G Contreras","year":"2005","unstructured":"Contreras G, Tozman E, Nahar N, Metz D (2005) Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14(Suppl 1):s33\u201338","journal-title":"Lupus"},{"key":"8963_CR65","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, D\u2019Cruz D, Sangle S et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083\u20132089","journal-title":"Ann Rheum Dis"},{"key":"8963_CR66","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","volume":"75","author":"F Tamirou","year":"2016","unstructured":"Tamirou F, D\u2019Cruz D, Sangle S et al (2016) Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75:526\u2013531","journal-title":"Ann Rheum Dis"},{"key":"8963_CR67","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886\u20131895","journal-title":"N Engl J Med"},{"key":"8963_CR68","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1177\/0961203311418269","volume":"20","author":"M Zeher","year":"2011","unstructured":"Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, Hiepe F, Prestele H, Bernhardt P, Amoura Z (2011) Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20:1484\u20131493","journal-title":"Lupus"},{"key":"8963_CR69","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, Vidal X, Mitjavila F, Salom\u00f3 AC, Pedragosa JC, Ortiz-Santamaria V, Plana MM, Cort\u00e9s-Hern\u00e1ndez J (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 76:1575\u20131582","journal-title":"Ann Rheum Dis"},{"key":"8963_CR70","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/1756-185X.12179","volume":"16","author":"F Yahya","year":"2013","unstructured":"Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S (2013) Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Int J Rheum Dis 16:724\u2013730","journal-title":"Int J Rheum Dis"},{"key":"8963_CR71","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3899\/jrheum.150779","volume":"43","author":"K Tselios","year":"2016","unstructured":"Tselios K, Gladman DD, Su J, Urowitz MB (2016) Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol 43:552\u2013558","journal-title":"J Rheumatol"},{"key":"8963_CR72","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s10067-019-04473-w","volume":"38","author":"M Kawazoe","year":"2019","unstructured":"Kawazoe M, Kaneko K, Yamada Z et al (2019) Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. Clin Rheumatol 38:1571\u20131578","journal-title":"Clin Rheumatol"},{"key":"8963_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/03009740701607042","volume":"36","author":"CC Mok","year":"2007","unstructured":"Mok CC (2007) Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 36:329\u2013337","journal-title":"Scand J Rheumatol"},{"issue":"22","key":"8963_CR74","first-page":"01692","volume":"S0140\u20136736","author":"ER Volkmann","year":"2022","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V (2022) Systemic sclerosis. Lancet S0140\u20136736(22):01692","journal-title":"Lancet"},{"key":"8963_CR75","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"8963_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/23971983211000971","volume":"7","author":"R Park","year":"2022","unstructured":"Park R, Nevskaya T, Baron M, Pope JE (2022) Immunosuppression use in early systemic sclerosis may be increasing over time. J Scleroderma Relat Disord 7:33\u201341","journal-title":"J Scleroderma Relat Disord"},{"key":"8963_CR77","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Tashkin DP, Li N et al (2017) Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol 69:1451\u20131460","journal-title":"Arthritis Rheumatol"},{"key":"8963_CR78","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"8963_CR79","doi-asserted-by":"publisher","first-page":"366","DOI":"10.46497\/ArchRheumatol.2020.7771","volume":"35","author":"K-A Lee","year":"2020","unstructured":"Lee K-A, Kim BY, Choi SJ, Kim S-K, Kim S-H, Kim H-S (2020) A real-world experience of mycophenolate mofetil for systemic sclerosis: a retrospective multicenter observational study. Arch Rheumatol 35:366\u2013375","journal-title":"Arch Rheumatol"},{"key":"8963_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9:96\u2013106","journal-title":"Lancet Respir Med"},{"key":"8963_CR81","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","volume":"30","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, Varga J, Matucci-Cerinic M, Khanna D (2021) New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs 30:635\u2013652","journal-title":"Expert Opin Investig Drugs"},{"key":"8963_CR82","unstructured":"Roth M (2022) Scleroderma lung study III (SLS III): combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease. clinicaltrials.gov"},{"key":"8963_CR83","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas R, Tashkin DP, Furst DE et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res 70:439\u2013444","journal-title":"Arthritis Care Res"},{"key":"8963_CR84","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","volume":"138","author":"M Hinchcliff","year":"2018","unstructured":"Hinchcliff M, Toledo DM, Taroni JN et al (2018) Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J Invest Dermatol 138:1301\u20131310","journal-title":"J Invest Dermatol"},{"key":"8963_CR85","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/jid.2013.130","volume":"133","author":"M Hinchcliff","year":"2013","unstructured":"Hinchcliff M, Huang C-C, Wood TA et al (2013) Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 133:1979\u20131989","journal-title":"J Invest Dermatol"},{"key":"8963_CR86","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/rheumatology\/kez658","volume":"59","author":"G De Luca","year":"2020","unstructured":"De Luca G, Campochiaro C, De Santis M et al (2020) Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology 59:2523\u20132533","journal-title":"Rheumatology"},{"issue":"4","key":"8963_CR87","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/rheumatology\/keac504","volume":"62","author":"S Panopoulos","year":"2023","unstructured":"Panopoulos S, Mavrogeni S, Vlachopoulos C, Sfikakis PP (2023) Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. Rheumatology (Oxford, England) 62(4):1535\u20131542. https:\/\/doi.org\/10.1093\/rheumatology\/keac504","journal-title":"Rheumatology (Oxford, England)"},{"key":"8963_CR88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7:86","journal-title":"Nat Rev Dis Primers"},{"key":"8963_CR89","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","volume":"14","author":"IE Lundberg","year":"2018","unstructured":"Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269\u2013278","journal-title":"Nat Rev Rheumatol"},{"key":"8963_CR90","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329\u2013340","journal-title":"Ann Rheum Dis"},{"issue":"SI2","key":"8963_CR91","doi-asserted-by":"publisher","first-page":"SI163","DOI":"10.1093\/rheumatology\/keac404","volume":"62","author":"GC Varnier","year":"2023","unstructured":"Varnier GC, Consolaro A, Cheng IL, Silva Riveiro A, Pilkington C, Ravelli A (2023) Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford, England) 62(SI2):SI163\u2013SI169. https:\/\/doi.org\/10.1093\/rheumatology\/keac404","journal-title":"Rheumatology (Oxford, England)"},{"key":"8963_CR92","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14:279\u2013289","journal-title":"Nat Rev Rheumatol"},{"key":"8963_CR93","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","volume":"107","author":"IC Mira-Avendano","year":"2013","unstructured":"Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, Culver DA (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis. Respir Med 107:890\u2013896","journal-title":"Respir Med"},{"key":"8963_CR94","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44:386\u2013389","journal-title":"Rheumatology (Oxford)"},{"key":"8963_CR95","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GRV, D\u2019Cruz DP (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46:516\u2013518","journal-title":"Rheumatology (Oxford)"},{"key":"8963_CR96","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142:65\u201369","journal-title":"Arch Dermatol"},{"key":"8963_CR97","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s10067-021-05590-1","volume":"40","author":"AM Nair","year":"2021","unstructured":"Nair AM, Mathew J, Goel R, Chebbi P, Mathew AJ, Arvind G, Yadav B, Rebekah G, Prakash JAJ, Danda D (2021) Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol 40:2805\u20132819","journal-title":"Clin Rheumatol"},{"key":"8963_CR98","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","volume":"156","author":"JA Huapaya","year":"2019","unstructured":"Huapaya JA, Silhan L, Pinal-Fernandez I et al (2019) Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 156:896\u2013906","journal-title":"Chest"},{"key":"8963_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"8963_CR100","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders H-J, Basu N et al (2020) ANCA-associated vasculitis Nat Rev Dis Primers 6:71","journal-title":"ANCA-associated vasculitis Nat Rev Dis Primers"},{"key":"8963_CR101","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2020.01.011","volume":"74","author":"F Salvador","year":"2020","unstructured":"Salvador F (2020) ANCA associated vasculitis. Eur J Intern Med 74:18\u201328","journal-title":"Eur J Intern Med"},{"key":"8963_CR102","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583\u20131594","journal-title":"Ann Rheum Dis"},{"key":"8963_CR103","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M et al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73:1366\u20131383","journal-title":"Arthritis Rheumatol"},{"key":"8963_CR104","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","volume":"23","author":"W Hu","year":"2008","unstructured":"Hu W, Liu C, Xie H, Chen H, Liu Z, Li L (2008) Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23:1307\u20131312","journal-title":"Nephrol Dial Transplant"},{"key":"8963_CR105","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.11801018","volume":"14","author":"J Tuin","year":"2019","unstructured":"Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, Sanders J-S, Stegeman CA (2019) Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol 14:1021\u20131028","journal-title":"Clin J Am Soc Nephrol"},{"key":"8963_CR106","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399\u2013405","journal-title":"Ann Rheum Dis"},{"key":"8963_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001195","volume":"6","author":"K Kuzuya","year":"2020","unstructured":"Kuzuya K, Morita T, Kumanogoh A (2020) Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis\u2014a meta-analysis. RMD Open 6:e001195","journal-title":"RMD Open"},{"key":"8963_CR108","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody\u2013associated vasculitis: a randomized controlled trial. JAMA 304:2381\u20132388","journal-title":"JAMA"},{"key":"8963_CR109","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","volume":"37","author":"A Berti","year":"2022","unstructured":"Berti A, Alsawas M, Jawaid T et al (2022) Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrol Dial Transplant 37:2190\u20132200","journal-title":"Nephrol Dial Transplant"},{"key":"8963_CR110","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384:599\u2013609","journal-title":"N Engl J Med"},{"key":"8963_CR111","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1136\/annrheumdis-2019-215123","volume":"79","author":"SV Moiseev","year":"2020","unstructured":"Moiseev SV, Smitienko I, Bulanov N, Karovaikina E, Novikov PI (2020) Changing landscape of immunosuppression in ANCA-associated vasculitis. Ann Rheum Dis 79:e59\u2013e59","journal-title":"Ann Rheum Dis"},{"key":"8963_CR112","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","volume":"62","author":"MP Manns","year":"2015","unstructured":"Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis \u2013 update 2015. J Hepatol 62:S100\u2013S111","journal-title":"J Hepatol"},{"key":"8963_CR113","first-page":"187","volume":"9","author":"F Sahebjam","year":"2015","unstructured":"Sahebjam F, Vierling JM (2015) Autoimmune hepatitis Front Med 9:187\u2013219","journal-title":"Autoimmune hepatitis Front Med"},{"key":"8963_CR114","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:971\u20131004","journal-title":"J Hepatol"},{"key":"8963_CR115","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","volume":"103","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Oo YH, Schramm C et al (2008) Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103:3063\u20133070","journal-title":"Am J Gastroenterol"},{"key":"8963_CR116","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","volume":"23","author":"B Terziroli Beretta-Piccoli","year":"2017","unstructured":"Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2017) Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol 23:6030\u20136048","journal-title":"World J Gastroenterol"},{"key":"8963_CR117","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","volume":"55","author":"K Zachou","year":"2011","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients. J Hepatol 55:636\u2013646","journal-title":"J Hepatol"},{"key":"8963_CR118","unstructured":"Radboud University Medical Center (2022) A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis. clinicaltrials.gov"},{"issue":"Suppl 126","key":"8963_CR119","first-page":"291","volume":"38","author":"F Luppi","year":"2020","unstructured":"Luppi F, Sebastiani M, Silva M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A (2020) Interstitial lung disease in Sj\u00f6gren\u2019s syndrome: a clinical review. Clin Exp Rheumatol 38(Suppl 126):291\u2013300","journal-title":"Clin Exp Rheumatol"},{"key":"8963_CR120","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1513\/AnnalsATS.202108-954RL","volume":"19","author":"AW Wong","year":"2022","unstructured":"Wong AW, Khor YH, Donohoe K et al (2022) Prescribing patterns and tolerability of mycophenolate and azathioprine in patients with nonidiopathic pulmonary fibrosis fibrotic interstitial lung disease. Ann Am Thorac Soc 19:863\u2013867","journal-title":"Ann Am Thorac Soc"},{"key":"8963_CR121","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50:776\u2013790","journal-title":"Semin Arthritis Rheum"},{"key":"8963_CR122","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640\u2013646","journal-title":"J Rheumatol"},{"key":"8963_CR123","doi-asserted-by":"crossref","unstructured":"Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A (2021) Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 10:2020\u20138\u20138","DOI":"10.7573\/dic.2020-8-8"},{"key":"8963_CR124","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","volume":"151","author":"J Morisset","year":"2017","unstructured":"Morisset J, Johannson KA, Vittinghoff E et al (2017) Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest 151:619\u2013625","journal-title":"Chest"},{"key":"8963_CR125","doi-asserted-by":"publisher","first-page":"2002872","DOI":"10.1183\/13993003.02872-2020","volume":"57","author":"A Adegunsoye","year":"2021","unstructured":"Adegunsoye A, Morisset J, Newton CA et al (2021) Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. Eur Respir J 57:2002872","journal-title":"Eur Respir J"},{"issue":"23","key":"8963_CR126","first-page":"00002","volume":"S2213\u20132600","author":"F Amati","year":"2023","unstructured":"Amati F, Spagnolo P, Oldham JM et al (2023) Treatable traits in interstitial lung diseases: a call to action. Lancet Respir Med S2213\u20132600(23):00002\u201300004","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"8963_CR127","doi-asserted-by":"publisher","first-page":"s39","DOI":"10.1191\/0961203305LU2116OA","volume":"14","author":"MY Karim","year":"2005","unstructured":"Karim MY, Abbs IC (2005) Mycophenolate mofetil in nonlupus glomerulonephropathy. Lupus 14(Suppl 1):s39\u201341","journal-title":"Lupus"},{"key":"8963_CR128","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"J-H Hou","year":"2017","unstructured":"Hou J-H, Le W-B, Chen N et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in iga nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788\u2013795","journal-title":"Am J Kidney Dis"},{"key":"8963_CR129","doi-asserted-by":"crossref","unstructured":"Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF (2020) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3:CD003965","DOI":"10.1002\/14651858.CD003965.pub3"},{"key":"8963_CR130","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","author":"RP Baughman","year":"2021","unstructured":"Baughman RP, Valeyre D, Korsten P et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.04079-2020","journal-title":"Eur Respir J"},{"key":"8963_CR131","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","volume":"27","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Chasler J, Wand AL et al (2021) Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent. J Card Fail 27:1348\u20131358","journal-title":"J Card Fail"},{"key":"8963_CR132","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/01.wnl.0000341278.26993.22","volume":"72","author":"M Moravan","year":"2009","unstructured":"Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337\u2013340","journal-title":"Neurology"},{"key":"8963_CR133","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12016-015-8492-9","volume":"49","author":"RP Baughman","year":"2015","unstructured":"Baughman RP, Lower EE (2015) Treatment of sarcoidosis. Clin Rev Allergy Immunol 49:79\u201392","journal-title":"Clin Rev Allergy Immunol"},{"key":"8963_CR134","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/17512433.2022.2032657","volume":"15","author":"P Mangialardi","year":"2022","unstructured":"Mangialardi P, Harper R, Albertson TE (2022) The pharmacotherapeutics of sarcoidosis. Expert Rev Clin Pharmacol 15:51\u201364","journal-title":"Expert Rev Clin Pharmacol"},{"key":"8963_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101840","volume":"58","author":"S Papiris","year":"2019","unstructured":"Papiris S, Stagaki E, Papadaki G et al (2019) Mycophenolate mofetil as an alternative treatment in sarcoidosis. Pulm Pharmacol Ther 58:101840","journal-title":"Pulm Pharmacol Ther"},{"key":"8963_CR136","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ndt\/gfaa083","volume":"36","author":"V Raglianti","year":"2021","unstructured":"Raglianti V, Rossi GM, Vaglio A (2021) Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 36:1773\u20131781","journal-title":"Nephrol Dial Transplant"},{"key":"8963_CR137","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7326\/0003-4819-154-1-201101040-00005","volume":"154","author":"PJ Scheel","year":"2011","unstructured":"Scheel PJ, Feeley N, Sozio SM (2011) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 154:31\u201336","journal-title":"Ann Intern Med"},{"key":"8963_CR138","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford) 58:52\u201360","journal-title":"Rheumatology (Oxford)"},{"key":"8963_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06528-5","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li R, Luo X et al (2023) Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-023-06528-5","journal-title":"Clin Rheumatol"},{"key":"8963_CR140","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","volume":"385","author":"CA Bradbury","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q et al (2021) Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med 385:885\u2013895","journal-title":"N Engl J Med"},{"key":"8963_CR141","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-0609.2005.00437.x","volume":"75","author":"R Kotb","year":"2005","unstructured":"Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy J-F, Tchernia G, Goujard C (2005) Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 75:60\u201364","journal-title":"Eur J Haematol"},{"key":"8963_CR142","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jama.2019.12618","volume":"322","author":"SR Rathinam","year":"2019","unstructured":"Rathinam SR, Gonzales JA, Thundikandy R et al (2019) Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322:936\u2013945","journal-title":"JAMA"},{"key":"8963_CR143","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","volume":"142","author":"S Beissert","year":"2006","unstructured":"Beissert S, Werfel T, Frieling U et al (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142:1447\u20131454","journal-title":"Arch Dermatol"},{"key":"8963_CR144","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","volume":"143","author":"S Beissert","year":"2007","unstructured":"Beissert S, Werfel T, Frieling U et al (2007) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 143:1536\u20131542","journal-title":"Arch Dermatol"},{"key":"8963_CR145","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","volume":"57","author":"C Chams-Davatchi","year":"2007","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al (2007) Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 57:622\u2013628","journal-title":"J Am Acad Dermatol"},{"key":"8963_CR146","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"384","author":"VP Werth","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D et al (2021) Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med 384:2295\u20132305","journal-title":"N Engl J Med"},{"key":"8963_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103181","volume":"55","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ma J, Chang H, Zhang X, Yin L (2021) Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Multiple Sclerosis and Related Disorders 55:103181","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"8963_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101906","volume":"39","author":"A Borhani-Haghighi","year":"2020","unstructured":"Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, Shapiro L (2020) Neuro-Behcet\u2019s disease: an update on diagnosis, differential diagnoses, and treatment. Multiple Sclerosis and Related Disorders 39:101906","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"8963_CR149","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","volume":"24","author":"M Behrend","year":"2001","unstructured":"Behrend M (2001) Adverse gastrointestinal effects of mycophenolate mofetil. Drug-Safety 24:645\u2013663","journal-title":"Drug-Safety"},{"key":"8963_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124205","volume":"10","author":"MA Omair","year":"2015","unstructured":"Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review PLoS One 10:e0124205","journal-title":"A systematic review PLoS One"},{"key":"8963_CR151","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.tp.0000225760.09969.1f","volume":"82","author":"S Bunnapradist","year":"2006","unstructured":"Bunnapradist S, Lentine KL, Burroughs TE, Pinsky BW, Hardinger KL, Brennan DC, Schnitzler MA (2006) Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82:102","journal-title":"Transplantation"},{"key":"8963_CR152","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/CEG.S81922","volume":"8","author":"B Manger","year":"2015","unstructured":"Manger B, Hiepe F, Schneider M, Worm M, Wimmer P, Paulus E-M, Schwarting A (2015) Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol 8:205\u2013213","journal-title":"Clin Exp Gastroenterol"},{"key":"8963_CR153","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00296-015-3265-6","volume":"35","author":"A Subedi","year":"2015","unstructured":"Subedi A, Magder LS, Petri M (2015) Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. Rheumatol Int 35:1687\u20131692","journal-title":"Rheumatol Int"},{"key":"8963_CR154","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1399-3062.2009.00407.x","volume":"11","author":"ML Ritter","year":"2009","unstructured":"Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11:290\u2013297","journal-title":"Transpl Infect Dis"},{"key":"8963_CR155","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2893.1999.00163.x","volume":"6","author":"ZJ Gong","year":"1999","unstructured":"Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, Yap SH (1999) Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 6:229\u2013236","journal-title":"J Viral Hepat"},{"key":"8963_CR156","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2045-3701-3-22","volume":"3","author":"T Hawley","year":"2013","unstructured":"Hawley T, Spear M, Guo J, Wu Y (2013) Inhibition of HIV replication in vitro by clinical immunosuppressants and chemotherapeutic agents. Cell Biosci 3:22","journal-title":"Cell Biosci"},{"key":"8963_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085832","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Wang B, Huang S et al (2014) Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model. PLoS ONE 9:e85832","journal-title":"PLoS ONE"},{"key":"8963_CR158","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00007890-200101150-00026","volume":"71","author":"Z Ben-Ari","year":"2001","unstructured":"Ben-Ari Z, Zemel R, Tur-Kaspa R (2001) The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance\u2013no beneficial effect. Transplantation 71:154\u2013156","journal-title":"Transplantation"},{"key":"8963_CR159","doi-asserted-by":"crossref","unstructured":"Schiffer JT, Levy C, Hughes SM et al (2022) Stable HIV reservoir despite prolonged low-dose mycophenolate to limit CD4+ T-cell proliferation. Open Forum Infect Dis 9:ofac620","DOI":"10.1093\/ofid\/ofac620"},{"key":"8963_CR160","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/acr.24584","volume":"74","author":"W-H Wang","year":"2022","unstructured":"Wang W-H, Lai C-C, Huang Y-F, Li T-H, Tsao Y-P, Chen W-S, Chang Y-S (2022) Pneumocystis Jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Arthritis Care Res (Hoboken) 74:1444\u20131450","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8963_CR161","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","volume":"40","author":"H-C Hsu","year":"2021","unstructured":"Hsu H-C, Chang Y-S, Hou T-Y et al (2021) Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol 40:3755\u20133763","journal-title":"Clin Rheumatol"},{"key":"8963_CR162","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, Nikiphorou E, Dey M et al (2022) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis ard-2022\u2013223335","DOI":"10.1136\/rmdopen-2022-002726"},{"key":"8963_CR163","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/lt.20219","volume":"10","author":"JI Herrero","year":"2004","unstructured":"Herrero JI, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J (2004) Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl 10:1140\u20131143","journal-title":"Liver Transpl"},{"key":"8963_CR164","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0961203320923739","volume":"29","author":"CC Mok","year":"2020","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY (2020) Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus 29:836\u2013844","journal-title":"Lupus"},{"key":"8963_CR165","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/cid\/ciab125","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Wu X, Forshee R et al (2021) Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 73:941\u2013948","journal-title":"Clin Infect Dis"},{"key":"8963_CR166","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330\u20131338","journal-title":"Ann Rheum Dis"},{"key":"8963_CR167","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ajt.16851","volume":"22","author":"M Kantauskaite","year":"2022","unstructured":"Kantauskaite M, M\u00fcller L, Kolb T et al (2022) Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant 22:634\u2013639","journal-title":"Am J Transplant"},{"key":"8963_CR168","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/annrheumdis-2021-221252","volume":"81","author":"CM Connolly","year":"2022","unstructured":"Connolly CM, Chiang TP-Y, Boyarsky BJ et al (2022) Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Ann Rheum Dis 81:293\u2013295","journal-title":"Ann Rheum Dis"},{"key":"8963_CR169","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","volume":"5","author":"R Robson","year":"2005","unstructured":"Robson R, Cecka JM, Opelz G, Budde M, Sacks S (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5:2954\u20132960","journal-title":"Am J Transplant"},{"key":"8963_CR170","doi-asserted-by":"publisher","first-page":"685","DOI":"10.12659\/AOT.889299","volume":"18","author":"A Kaltenborn","year":"2013","unstructured":"Kaltenborn A, Schrem H (2013) Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 18:685\u2013696","journal-title":"Ann Transplant"},{"key":"8963_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101698","volume":"75","author":"EX Shao","year":"2022","unstructured":"Shao EX, Betz-Stablein B, Marquat L, Campbell S, Isbel N, Green AC, Plasmeijer EI (2022) Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients. Transpl Immunol 75:101698","journal-title":"Transpl Immunol"},{"key":"8963_CR172","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.chest.2021.12.636","volume":"161","author":"SD Lok","year":"2022","unstructured":"Lok SD, Wong AW, Khor YH, Ryerson CJ, Johannson KA, Investigators CARE-PF (2022) Malignancy risk associated with mycophenolate mofetil or azathioprine in patients with fibrotic interstitial lung disease. Chest 161:1594\u20131597","journal-title":"Chest"},{"key":"8963_CR173","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-0035-1556743","volume":"4","author":"LA Coscia","year":"2015","unstructured":"Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ (2015) Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet 4:42\u201355","journal-title":"J Pediatr Genet"},{"key":"8963_CR174","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajmg.a.35223","volume":"158A","author":"M Hoeltzenbein","year":"2012","unstructured":"Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C (2012) Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A:588\u2013596","journal-title":"Am J Med Genet A"},{"key":"8963_CR175","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/BOR.0000000000000710","volume":"32","author":"M Birru Talabi","year":"2020","unstructured":"Birru Talabi M, Clowse MEB (2020) Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol 32:238","journal-title":"Curr Opin Rheumatol"},{"key":"8963_CR176","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795\u2013810","journal-title":"Ann Rheum Dis"},{"key":"8963_CR177","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.kint.2021.05.010","volume":"100","author":"A Huerta","year":"2021","unstructured":"Huerta A, Caballero Bermejo AF, de Villa LF, Sedano R, Ruiz-Antor\u00e1n B, Avenda\u00f1o-Sol\u00e1 C, Portoles P\u00e9rez J, Sancho-L\u00f3pez A (2021) Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis. Kidney Int 100:711","journal-title":"Kidney Int"},{"key":"8963_CR178","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074\u2013D1082","journal-title":"Nucleic Acids Res"},{"key":"8963_CR179","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ajhp\/54.3.285","volume":"54","author":"KA Hood","year":"1997","unstructured":"Hood KA, Zarembski DG (1997) Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 54:285\u2013294","journal-title":"Am J Health Syst Pharm"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-023-08963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-023-08963-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-023-08963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T10:59:47Z","timestamp":1702637987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-023-08963-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["8963"],"URL":"https:\/\/doi.org\/10.1007\/s12016-023-08963-3","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"3 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}